Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Cancer Res. 2020 Nov 4;81(1):174–186. doi: 10.1158/0008-5472.CAN-20-1710

Figure 6. IFN-β is required for ZMYND8 loss-mediated antitumor effect.

Figure 6.

SC and ZMYND8 KO2 PY8119 cells were orthotopically implanted into the mammary fat pad of female C57BL/6J mice, respectively. 5 mice each group were administrated with monoclonal anti-IFNAR1 depleting antibody (mAb). (A) Tumor growth curve (n = 5, mean ± SEM). (B) Tumor image on day 30. (C) Tumor weight on day 30 (n = 5, mean ± SEM). (D) Immunoblot analysis of ZMYND8 and actin in tumors. *p < 0.05; **p < 0.01, ***p < 0.001 by two-way ANOVA with Tukey’s test.